High manufacturing costs, lack of funding, and varying regulatory standards have restricted patient access.

This highlights the urgent need for systemic solutions to democratize cell therapy and ensure broader patient reach.

#DeSci #Biotech

https://www.nature.com/articles/s41587-025-02625-9